T-cell studies on patients with mild versus severe COVID-19 have in both cases shown a robust specific T-cell response (both CD4+ and CD8+ T-cells) but the T-cell phenotypes (e.g., cytokine production and dominant T-cell subset) differ between the two disease severity groups [39,40]. The gene discussed is CD8A; the disease is COVID-19.